Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development
Open Access
- 20 March 2018
- journal article
- review article
- Published by Springer Science and Business Media LLC in npj Vaccines
- Vol. 3 (1), 1-12
- https://doi.org/10.1038/s41541-018-0049-5
Abstract
Lassa fever (LF) is a zoonotic disease associated with acute and potentially fatal hemorrhagic illness caused by the Lassa virus (LASV), a member of the family Arenaviridae. It is generally assumed that a single infection with LASV will produce life-long protective immunity. This suggests that protective immunity induced by vaccination is an achievable goal and that cell-mediated immunity may play a more important role in protection, at least following natural infection. Seropositive individuals in endemic regions have been shown to have LASV-specific T cells recognizing epitopes for nucleocapsid protein (NP) and glycoprotein precursor (GPC), suggesting that these will be important vaccine immunogens. The role of neutralizing antibodies in protective immunity is still equivocal as recent studies suggest a role for neutralizing antibodies. There is extensive genetic heterogeneity among LASV strains that is of concern in the development of assays to detect and identify all four LASV lineages. Furthermore, the gene disparity may complicate the synthesis of effective vaccines that will provide protection across multiple lineages. Non-human primate models of LASV infection are considered the gold standard for recapitulation of human LF. The most promising vaccine candidates to date are the ML29 (a live attenuated reassortant of Mopeia and LASV), vesicular stomatitis virus (VSV) and vaccinia-vectored platforms based on their ability to induce protection following single doses, high rates of survival following challenge, and the use of live virus platforms. To date no LASV vaccine candidates have undergone clinical evaluation.Keywords
This publication has 144 references indexed in Scilit:
- Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal ElectroporationVaccines, 2013
- Rapid and Specific Detection of Lassa Virus by Reverse Transcription-PCR Coupled with Oligonucleotide Array HybridizationJournal of Clinical Microbiology, 2012
- Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse modelVaccine, 2012
- Evaluation of Lassa antiviral compound ST-193 in a guinea pig modelAntiviral Research, 2011
- Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigsVaccine, 2011
- Rapid detection of Lassa virus by reverse transcription-loop-mediated isothermal amplificationMicrobiology and Immunology, 2010
- Improved Detection of Lassa Virus by Reverse Transcription-PCR Targeting the 5′ Region of S RNAJournal of Clinical Microbiology, 2010
- Modern Uses of Electron Microscopy for Detection of VirusesClinical Microbiology Reviews, 2009
- Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primatesVaccine, 2008
- A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunityVaccine, 2007